Literature DB >> 9414184

The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval.

J R Riera1, C Astengo-Osuna, J A Longmate, H Battifora.   

Abstract

The immunohistochemical diagnosis between epithelial mesothelioma and adenocarcinoma is currently based on the use of a panel of antibodies to adenocarcinoma-associated antigens and a few antibodies to mesothelial-associated antigens. Since the introduction of epitope retrieval methods, the sensitivity of many antibodies has been enhanced. Thus, a reevaluation of the mesothelioma/adenocarcinoma diagnostic panel becomes necessary. We studied 268 paraffin-embedded formalin-fixed tumor samples that included 57 epithelial mesotheliomas and 211 adenocarcinomas of various origins, comparing an extensive antibody panel with and without heat-induced epitope retrieval (HIER). Marked increase in the sensitivity of several antibodies, with no loss of specificity, was found when HIER was used. After statistical analysis, the antibodies to the epithelial glycoproteins carcinoembryonic antigen, BerEp4, and Bg8 emerged as the best discriminators between adenocarcinoma and epithelial mesothelioma within the entire panel. The mesothelium-associated antibodies, HBME-1, calretinin, and thrombomodulin were less sensitive and less specific than the former, although they were found to be useful on certain cases. Antibodies to cytokeratins and vimentin, although of minor diagnostic value in this context, may be helpful to evaluate the quality of antigen preservation. This study confirms the value of immunohistochemistry to accurately distinguish mesothelioma from adenocarcinoma when an antibody panel approach is used. The addition of heat-induced epitope retrieval methods increases the effectiveness of the procedure and is recommended for most of the antibody panel members.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9414184     DOI: 10.1097/00000478-199712000-00003

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  14 in total

1.  Establishment of permanent cell lines purified from human mesothelioma: morphological aspects, new marker expression and karyotypic analysis.

Authors:  Marie-Marthe Philippeaux; Jean-Claude Pache; Sophie Dahoun; Marc Barnet; John-Henri Robert; Jacques Mauël; Anastase Spiliopoulos
Journal:  Histochem Cell Biol       Date:  2004-09-15       Impact factor: 4.304

2.  Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice.

Authors:  Brian Cooley; William Funkhouser; Dougald Monroe; Ashley Ezzell; David M Mann; Feng-Chang Lin; Paul E Monahan; Darrel W Stafford
Journal:  Blood       Date:  2016-04-22       Impact factor: 22.113

3.  My approach to the diagnosis of mesothelial lesions.

Authors:  K J Butnor
Journal:  J Clin Pathol       Date:  2006-06       Impact factor: 3.411

4.  Severe chromosomal aberrations in pleural mesotheliomas with unusual mesodermal features. Comparative genomic hybridization evidence for a mesothelioma subgroup.

Authors:  M Krismann; K M Müller; M Jaworska; G Johnen
Journal:  J Mol Diagn       Date:  2000-11       Impact factor: 5.568

Review 5.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

6.  A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma.

Authors:  Hila Benjamin; Danit Lebanony; Shai Rosenwald; Lahav Cohen; Hadas Gibori; Naama Barabash; Karin Ashkenazi; Eran Goren; Eti Meiri; Sara Morgenstern; Marina Perelman; Iris Barshack; Yaron Goren; Tina Bocker Edmonston; Ayelet Chajut; Ranit Aharonov; Zvi Bentwich; Nitzan Rosenfeld; Dalia Cohen
Journal:  J Mol Diagn       Date:  2010-09-23       Impact factor: 5.568

7.  The immunohistochemical characterization of sarcomatoid malignant mesothelioma of the pleura.

Authors:  Lucian R Chirieac; Geraldine S Pinkus; Jack L Pinkus; John Godleski; David J Sugarbaker; Joseph M Corson
Journal:  Am J Cancer Res       Date:  2010-09-30       Impact factor: 6.166

8.  Malignant mesothelioma: a comparison of biopsy and postmortem material by light microscopy and immunohistochemistry.

Authors:  F Roberts; A E McCall; R A Burnett
Journal:  J Clin Pathol       Date:  2001-10       Impact factor: 3.411

9.  Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition.

Authors:  Ausra Bendoraite; Emily C Knouf; Kavita S Garg; Rachael K Parkin; Evan M Kroh; Kathy C O'Briant; Aviva P Ventura; Andrew K Godwin; Beth Y Karlan; Charles W Drescher; Nicole Urban; Beatrice S Knudsen; Muneesh Tewari
Journal:  Gynecol Oncol       Date:  2009-10-24       Impact factor: 5.482

10.  Specificity of MOC-31 and HBME-1 immunohistochemistry in the differential diagnosis of adenocarcinoma and malignant mesothelioma: a study on environmental malignant mesothelioma cases from Turkish villages.

Authors:  Derya Gümürdülü; E Handan Zeren; Philip T Cagle; Fazilet Kayasel uk; Nazan Alparslan; Ali Kocabas; Ilhan Tuncer
Journal:  Pathol Oncol Res       Date:  2003-01-06       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.